Trial Profile

An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease Patients

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simufilam (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors Cassava Sciences

Most Recent Events

25 May 2053 Primary end point has been changed from ADAS-Cog11 to Adverse Event Monitoring thus changing trial focus from "TU" to "AR".
03 Feb 2025 Status changed from completed to discontinued.
14 Jan 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com